PE20231952A1 - Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina - Google Patents
Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicininaInfo
- Publication number
- PE20231952A1 PE20231952A1 PE2023001563A PE2023001563A PE20231952A1 PE 20231952 A1 PE20231952 A1 PE 20231952A1 PE 2023001563 A PE2023001563 A PE 2023001563A PE 2023001563 A PE2023001563 A PE 2023001563A PE 20231952 A1 PE20231952 A1 PE 20231952A1
- Authority
- PE
- Peru
- Prior art keywords
- treatment
- formula
- compounds
- nk2r
- serine
- Prior art date
Links
- 102000007124 Tachykinin Receptors Human genes 0.000 title 1
- 108010072901 Tachykinin Receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 abstract 3
- KFHRMMHGGBCRIV-UHFFFAOYSA-N 2-azaniumyl-4-methoxybutanoate Chemical compound COCCC(N)C(O)=O KFHRMMHGGBCRIV-UHFFFAOYSA-N 0.000 abstract 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical group NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract 2
- 101000600912 Homo sapiens Substance-K receptor Proteins 0.000 abstract 2
- JZKXXXDKRQWDET-QMMMGPOBSA-N L-m-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-QMMMGPOBSA-N 0.000 abstract 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 abstract 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 2
- 102100037342 Substance-K receptor Human genes 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- JZKXXXDKRQWDET-UHFFFAOYSA-N meta-tyrosine Natural products OC(=O)C(N)CC1=CC=CC(O)=C1 JZKXXXDKRQWDET-UHFFFAOYSA-N 0.000 abstract 2
- 239000004475 Arginine Substances 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 abstract 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical group CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract 1
- 239000004472 Lysine Substances 0.000 abstract 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract 1
- 239000004473 Threonine Substances 0.000 abstract 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 abstract 1
- 229960000310 isoleucine Drugs 0.000 abstract 1
- 229930182817 methionine Natural products 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/22—Tachykinins, e.g. Eledoisins, Substance P; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20206509 | 2020-11-09 | ||
| PCT/EP2021/081057 WO2022096736A1 (en) | 2020-11-09 | 2021-11-09 | Compounds and their use in treatment of tachykinin receptor mediated disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231952A1 true PE20231952A1 (es) | 2023-12-06 |
Family
ID=73198203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001563A PE20231952A1 (es) | 2020-11-09 | 2021-11-09 | Compuestos y su uso en el tratamiento de trastornos mediados por receptores de taquicinina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230406883A1 (enExample) |
| EP (1) | EP4240749A1 (enExample) |
| JP (1) | JP2023551122A (enExample) |
| KR (1) | KR20230106616A (enExample) |
| CN (1) | CN116745310A (enExample) |
| AU (1) | AU2021374843A1 (enExample) |
| CA (1) | CA3197916A1 (enExample) |
| CL (1) | CL2023001325A1 (enExample) |
| CO (1) | CO2023007404A2 (enExample) |
| IL (1) | IL302745A (enExample) |
| MX (1) | MX2023005408A (enExample) |
| PE (1) | PE20231952A1 (enExample) |
| WO (1) | WO2022096736A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240118914A (ko) | 2021-01-20 | 2024-08-05 | 바이킹 테라퓨틱스 인코포레이티드 | 대사 및 간 질환 치료를 위한 조성물 및 방법 |
| CA3231953A1 (en) | 2021-09-15 | 2023-03-23 | Brian Lian | Compositions and methods for the treatment of metabolic and liver disorders |
| WO2023118263A1 (en) * | 2021-12-21 | 2023-06-29 | Embark Biotech Aps | Agonists for treatment of eating disorder |
| CN117384258B (zh) * | 2023-10-12 | 2024-07-26 | 湖南中晟全肽生物科技股份有限公司 | 一种神经激肽受体2（nk2r）激动剂及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2660247A3 (en) * | 2009-05-08 | 2014-09-03 | Chongxi Yu | High penetration prodrug compositions of peptides and peptide-related compounds |
| CA2918245C (en) * | 2013-08-01 | 2022-08-30 | Dignify Therapeutics, Inc. | Compositions and methods for inducing urinary voiding and defecation |
| WO2015071355A1 (en) * | 2013-11-15 | 2015-05-21 | Novo Nordisk A/S | Selective pyy compounds and uses thereof |
| MX392572B (es) * | 2015-06-12 | 2025-03-24 | Novo Nordisk As | Compuestos del péptido yy (pyy) selectivos y sus usos. |
| US11352391B2 (en) * | 2017-09-21 | 2022-06-07 | Dignify Therapeutics, Llc | Compositions for inducing urinary voiding and defecation |
| PE20210473A1 (es) * | 2018-05-04 | 2021-03-08 | Novo Nordisk As | Derivados de gip y usos de estos |
| KR20220084035A (ko) * | 2019-10-17 | 2022-06-21 | 유니버시티 오브 코펜하겐 | Tacr2의 효능제 |
-
2021
- 2021-11-09 IL IL302745A patent/IL302745A/en unknown
- 2021-11-09 CN CN202180089751.3A patent/CN116745310A/zh active Pending
- 2021-11-09 WO PCT/EP2021/081057 patent/WO2022096736A1/en not_active Ceased
- 2021-11-09 PE PE2023001563A patent/PE20231952A1/es unknown
- 2021-11-09 CA CA3197916A patent/CA3197916A1/en active Pending
- 2021-11-09 JP JP2023528102A patent/JP2023551122A/ja not_active Ceased
- 2021-11-09 AU AU2021374843A patent/AU2021374843A1/en active Pending
- 2021-11-09 MX MX2023005408A patent/MX2023005408A/es unknown
- 2021-11-09 EP EP21802379.4A patent/EP4240749A1/en active Pending
- 2021-11-09 KR KR1020237016448A patent/KR20230106616A/ko active Pending
- 2021-11-09 US US18/252,056 patent/US20230406883A1/en active Pending
-
2023
- 2023-05-08 CL CL2023001325A patent/CL2023001325A1/es unknown
- 2023-06-05 CO CONC2023/0007404A patent/CO2023007404A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022096736A1 (en) | 2022-05-12 |
| US20230406883A1 (en) | 2023-12-21 |
| CA3197916A1 (en) | 2022-05-12 |
| CL2023001325A1 (es) | 2023-12-15 |
| MX2023005408A (es) | 2023-07-25 |
| AU2021374843A1 (en) | 2023-06-08 |
| KR20230106616A (ko) | 2023-07-13 |
| AU2021374843A9 (en) | 2024-08-08 |
| JP2023551122A (ja) | 2023-12-07 |
| CO2023007404A2 (es) | 2023-07-10 |
| EP4240749A1 (en) | 2023-09-13 |
| IL302745A (en) | 2023-07-01 |
| CN116745310A (zh) | 2023-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090932A1 (es) | Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1 | |
| RU2012101274A (ru) | Соединения глюкагона, активные в отношении рецептора gip | |
| ES2558330T3 (es) | Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo | |
| PE20190355A1 (es) | Derivado de glucagon, conjugado del mismo, composicion que comprende el mismo y uso terapeutico del mismo | |
| RU2011134596A (ru) | Аналоги оксинтомодулина | |
| AR064555A1 (es) | Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo | |
| JPH0532696A (ja) | 副甲状腺ホルモン誘導体 | |
| AR065349A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| ES2651946T3 (es) | Utilización de péptidos CD31 en el tratamiento de trastornos trombóticos y autoinmunes | |
| CN113072617B (zh) | 一种多肽化合物及其应用 | |
| AR072160A1 (es) | Co-agonistas del receptor de glucagon/glp-1 | |
| PE20090682A1 (es) | Secuencias peptidicas y composiciones | |
| JPS63313800A (ja) | 副甲状腺ホルモン拮抗剤 | |
| CA2456964A1 (en) | Melanin-concentrating hormone antagonists | |
| WO2019087161A1 (en) | Peptide conjugate cgrp receptor antagonists and methods of preparation and uses thereof | |
| AU664855B2 (en) | Lanthionine bridged peptides | |
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| JP2023551122A5 (enExample) | ||
| AR049149A1 (es) | Analogos antagonistas de gh-rh | |
| AU2013277637C1 (en) | Synthesis of beta-turn peptidomimetic cyclic compounds | |
| EP4077348A1 (en) | Retro-inverso peptides | |
| CA2399509A1 (en) | Melanin-concentrating hormone analogs | |
| ATE541932T1 (de) | Herstellung von glucagonähnlichem peptid 2 und analogen | |
| AR108969A1 (es) | Derivado de glucagón, un conjugado del mismo, y una composición que comprende el mismo, y un uso terapéutico del mismo | |
| CA2473229A1 (en) | Selective melanin-concentrating hormone type -1 receptor agonists |